The committee's approval comes days after the FDA shared details on a small number of trial participants who developed myocarditis or pericarditis after receiving the vaccine.  

Drug shortages have been impacted by COVID-19, with 95% of doctors believing the pandemic exposed weaknesses in the medicine supply chain.

Michael J. Barry, MD, vice chair of the U.S. Preventive Services Task Force, gave Cardiovascular Business an overview of the new recommendations.

These recommendations, the group emphasized, do not include patients with a history of CVD or those who are already taking aspirin for another reason.

The recall is focused on a single batch distributed from December 2021 to March 2022.

Machine learning is playing a key role in predicting all major forms of drug cardiotoxicity, potentially helping reduce late-stage clinical trial failures.

The latest numbers on cardiovascular deaths put the focus on innovative ways to point the trend line down again.